See in
High DEF(INITY)™

A clearer echo.
A better treatment plan.

Your decisions have real-life consequences. High DEF(INITY)™, high-resolution echocardiograms help answer clinical questions and improve patient management.1

Your decisions have real-life consequences. High DEF(INITY)™, high-resolution echocardiograms help answer clinical questions and improve patient management.1

DEFINITY® provides prolonged enhancement at a low dose so your patients get the accurate echoes and diagnoses they deserve.1,2

IN THE US
4 OUT OF 5

contrast-enhanced echoes are performed with DEFINITY®3

INCLUDED IN OVER
2200

peer-reviewed publications4

MORE THAN
18 million

studies performed5

DEFINITY® vial.

DEFINITY® produces high-quality, consistent, and reliable images6-9

Our advanced microbubble technology helps you see in High DEF(INITY)™ with proven safety and consistent quality from echo to echo.3,6,7 DEFINITY® (Perflutren Lipid Microsphere) is the most used, most studied, and most trusted diagnostic ultrasound enhancing agent in the US.3‑5

DEFINITY® RT vial.

DEFINITY® RT

Trusted DEFINITY® efficacy and safety with room temperature storage3,6,10

Safety

Demonstrated across gender, race, and age3

LEARN MORE
Efficacy

Facts about how DEFINITY® works

LEARN MORE
Case Studies

Real-world experiences

LEARN MORE

What is DEFINITY®?

DEFINITY® is a diagnostic ultrasound enhancing agent that opacifies the left ventricular chamber and improves the delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms.6

Move the slider to see in High DEF(INITY)™

DEFINITY®
Unenhanced

To avoid potential patient risks and institutional complexities, DEFINITY® does not contain these ingredients6:

  • Iodine

  • Radioactive materials

  • Gadolinium

  • Sulfur components

  • Blood products

Sign up for DEFINITY® updates and announcements
SIGN UP HERE
Order DEFINITY® products
ORDER HERE
Know your suboptimal echo rate.
Ask about the IMPROVE program.
LEARN MORE
Learn about Diagnostic Challenges

References:

  1. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.

  2. Becher H, Burns PN. Handbook of Contrast Echocardiography. Heidelberg, NY: Springer-Verlag; 2000:2-44.

  3. Data on file, Lantheus Medical Imaging, Inc.

  4. Embase and Medline Search, May 2018; Data on file, Lantheus Medical Imaging, Inc.

  5. ©2021 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.

  6. DEFINITY® [package insert]. N. Billerica, MA: Lantheus Medical Imaging, Inc.

  7. Sboros V, Moran CM, Pye SD, McDicken WN. Contrast agent stability: a continuous B-mode imaging approach. Ultrasound Med Biol. 2001;27(10):1367-1377.

  8. Sonne C, Xie F, Lof J, et al. Differences in definity and optison microbubble destruction rates at a similar mechanical index with different real-time perfusion systems. J Am Soc Echocardiogr. 2003;16(11):1178-1185.

  9. Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86(6):669-674.

  10. DEFINITY® RT [package insert]. N. Billerica, MA: Lantheus Medical Imaging, Inc.